-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Recently, the U.
FTD aims to accelerate the development and rapid review of drugs for serious diseases to address serious unmet medical needs in key areas
Currently, Akero is conducting two parallel phase 2b clinical trials to evaluate the efficacy and safety of efruxifermin in the treatment of patients with NASH
NASH is a serious and potentially life-threatening disease and is the leading cause of liver failure and liver transplantation worldwide
efruxifermin is a differentiated Fc-FGF21 fusion protein, which is engineered to mimic the balanced biological activity characteristics of natural FGF21
FTD qualification is an important step in advancing the efruxifermin project, and it has the potential to bring the drug to more patients affected by NASH
The FDA granted efruxifermin FTD based on recent clinical milestones to demonstrate the potential of efruxifermin in addressing NASH and reversing multiple drivers of fibrosis
Reference source: Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH